12 Aug, EOD - Indian

Nifty Pharma 21753.5 (0.69)

Nifty 50 24487.4 (-0.40)

Nifty Next 50 66223.9 (-0.09)

Nifty Midcap 100 56324.85 (-0.27)

Nifty Bank 55043.7 (-0.84)

Nifty Smallcap 100 17498.1 (0.04)

Nifty IT 34674.3 (0.38)

SENSEX 80235.59 (-0.46)

12 Aug, EOD - Global

NIKKEI 225 42718.17 (2.15)

HANG SENG 24969.69 (0.25)

S&P 6411.79 (0.27)


Live News

You are Here : Home > News > Live News >

(22 Apr 2024, 15:34)

Epigral jumps after Q4 PAT rises 57% QoQ to Rs 77 cr

Epigral rallied 3.06% to Rs 1,359.50 after the company’s net profit jumped 57.44% to Rs 77.27 crore on 11.26% increase in revenue from operations to Rs 524.63 crore in Q4 FY24 over Q3 FY24.


Profit before tax jumped 53.47% QoQ to Rs 113.46 crore in Q4 FY24.

EBITDA stood at Rs 155 crore in Q4 FY24, registering the growth of 27% as compared with Rs 123 crore posted in corresponding quarter last year. EBITDA margin stood at 30% in Q4 FY24 as against 26% in Q3 FY24 on account of increase in utilization and marginal improvement in spreads.

Revenue contribution from Derivatives & Specialty segment increased to 52% in Q4FY24 as compared with 38% in Q4FY23.

On operational front, the company’s capacity utilization jumped to 83% in Q4 FY24 from 81% in Q3 FY24. QoQ realizations dropped for all the products, except for caustic soda and hydrogen peroxide.

On FY24 basis, the company’s net profit declined 44.61% to Rs 195.81 crore in FY24 from Rs 353.51 crore posted in FY23. Revenue from operations fell 11.84% YoY to Rs 1929.19 crore in FY24.

Meanwhile, the company’s board declared final dividend of Rs 5 per equity share for FY2024.

Maulik Patel, chairman and managing director, Epigral, said, “The company performed better on sequential basis in every quarter starting from Q2FY24. Our 55% growth in PAT on a sequential basis stands out despite challenging macroeconomics, subdued demand and drop in realizations. It delivered volume growth of 15% in FY2024 and 9% YoY in Q4FY24, saw major growth coming in from new projects commissioned in FY2023. It ended FY24, with Q4FY24 witnessing, QoQ, revenue growth of 11% and with EBIDTA margin of 30%.

Its past capex drove volume growth in FY2024. Similarly, we recently commissioned CPVC Resin capacity (45,000 TPA) and in H1FY25 it expects to commission Chlorotoluenes Value Chain and CPVC Compound facility, that will drive growth for coming years. With our focus on expanding Derivatives & Specialty business, diversifying the business model and strengthening our integrated complex.”

Epigral, formerly known as Meghmani Finechem, is a leading integrated manufacturer of chemicals in India. The company is the first to set up an Epichlorohydrin plant in the country and is also the largest capacity plant of CPVC Resin. Epigral is also India’s fourth largest manufacturer of caustic soda, chlorine and hydrogen and a leading manufacturer of caustic potash, chloromethanes and hydrogen peroxide.

More News
More Company News View Company Information

Capital Market Publishers India Pvt. Ltd

401, Swastik Chambers, Sion Trombay Road, Chembur, Mumbai - 400 071, India.

Formed in 1986, Capital Market Publishers India Pvt Ltd pioneered corporate databases and stock market magazine in India. Today Capitaline corporate database cover more than 35,000 listed and unlisted Indian companies. Latest technologies and standards are constantly being adopted to keep the database user-friendly, comprehensive and up-to-date.

Over the years the scope of the databases has enlarged to cover economy, sectors, mutual funds, commodities and news. Many innovative online and offline applications of these databases have been developed to meet various common as well as customized requirements.

While all the leading institutional investors use Capitaline databases, Capital Market magazine gives access to the databases to individual investors through Corporate Scoreboard. Besides stock market and company-related articles, the magazine’s independent and insightful coverage includes mutual funds, taxation, commodities and personal finance.

Copyright @ Capital Market Publishers India Pvt.Ltd

Designed, Developed and maintained by CMOTS Infotech (ISO 9001:2015 Certified)

Site best viewed in Internet Explorer Edge ,   Google Chrome 115.0.5790.111 + ,   Mozilla Firefox 115.0.3 + ,   Opera 30.0+, Safari 16.4.1 +